Brenda Cirincione, PhD, Neuroma Therapeutics

Brenda Cirincione has over 25 years of research experience in Clinical Pharmacology and Pharmacometrics. She received a PhD in pharmaceutical sciences and an MA in statistics from the University of Buffalo, State University of New York. She has experience working in businesses across the pharmacometrics continuum: starting in a CRO (Cognigen), then a biotech (Amylin), biopharma (Bristol- Myers Squibb and Vertex) and most recently as the head of clinical pharmacology at Neuroma Therapeutics, allowing her expanded experience in drug development. She has experience across multiple therapeutics with both development and application of innovative and mechanism‐based clinical pharmacology models to optimize drug development and support approval for multiple therapeutic areas, populations in multiple countries. She is a past board member of the international society of pharmacometrics during which time she served in multiple leadership roles.